Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Arnold Ganser, Agnes Guerci-Bresler, Mathias Schmid, Kerry Taylor, Dominique Vassilieff, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, L. Agaoglu, G. Alimena, D. Alonso, S. Ame, E. Angelucci, B. Arrizabalaga, M. Athanasiou-MetaxaB. Augustson, Y. Aydinok, A. Baba, M. Baccarani, J. Beck, P. Beris, O. Beyne-Rauzy, H. Birgens, D. Bordessoule, C. Borgna-Pignatti, A. Bosly, K. Bouabdallah, D. Bowden, D. Bowen, D. Bron, M. D. Cappellini, M. Capra, G. Cartron, M. Cazzola, C. Chalkias, L. L. Chan, S. Chancharunee, C. Chapman, P. Charoenkwan, E. Chasapopoulou, S. Cheze, A. Chuansumrit, P. Cianciulli, C. Dauriac, M. Delforge, G. Dölken, H. Dombret, J. Duyster, T. Economopoulos, G. Ehninger, M. Elalfy, A. El-Beshlawy, L. Enggaard, G. Fillet, A. Filosa, G. Forni, R. Galanello, G. Gastl, S. Giraudier, A. Goldfarb, A. Grigg, F. Gumruk, S. Y. Ha, D. Haase, B. Heinrich, M. Hertzberg, J. Ho, H. C. Hsu, S. Huang, M. Hunault-Berger, B. Inusa, D. Jaulmes, J. Jensen, A. Kattamis, Y. Kilinc, K. H. Kim, S. Kinsey, L. Kjeldsen, A. Koren, M. E. Lai, Y. Lai, J. W. Lee, K. H. Lee, S. H. Lee, L. Legros, C. Li, C. K. Li, Q. Li, K. H. Lin, W. Linkesch, M. Lübbert, D. Lutz, A. J. Mohamed Thalha, G. Mufti, P. Muus, F. Nobile, N. Papadopoulos, S. Perrotta, M. Petrini, M. Pfeilstöcker, A. Piga, J. Poole, J. B. Porter, E. Pungolino, G. Quarta, C. Ravoet, H. H. Jolimont Lobbes, A. F. Remacha, L. Roy, G. Saglio, G. Sanz, M. Schmugge, H. Schots, G. Secchi, J. F. Seymour, F. Shah, H. Shah, Z. Shen, B. Slama, P. Sutcharitchan, A. Taher, H. Tamary, H. J. Tesch, S. L. Thein, J. Troncy, A. Villegas, V. Viprakasit, L. Wainwright, B. Wassmann, M. Wettervald, A. Will, B. Wörmann, J. Wright, S. P. Yeh, S. S. Yoon, N. C. Zoumbos, S. Zweegman

Research output: Contribution to journalArticle

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Original languageEnglish
Pages (from-to)1143-1150
Number of pages8
JournalLeukemia Research
Volume34
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Myelodysplastic Syndromes
Iron
Ferritins
Serum
Alanine Transaminase
deferasirox

Keywords

  • Deferasirox
  • Iron chelation therapy
  • Labile plasma iron
  • Myelodysplastic syndromes
  • Serum ferritin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes : Results from the large 1-year EPIC study. / Gattermann, Norbert; Finelli, Carlo; Della Porta, Matteo; Fenaux, Pierre; Ganser, Arnold; Guerci-Bresler, Agnes; Schmid, Mathias; Taylor, Kerry; Vassilieff, Dominique; Habr, Dany; Domokos, Gabor; Roubert, Bernard; Rose, Christian; Agaoglu, L.; Alimena, G.; Alonso, D.; Ame, S.; Angelucci, E.; Arrizabalaga, B.; Athanasiou-Metaxa, M.; Augustson, B.; Aydinok, Y.; Baba, A.; Baccarani, M.; Beck, J.; Beris, P.; Beyne-Rauzy, O.; Birgens, H.; Bordessoule, D.; Borgna-Pignatti, C.; Bosly, A.; Bouabdallah, K.; Bowden, D.; Bowen, D.; Bron, D.; Cappellini, M. D.; Capra, M.; Cartron, G.; Cazzola, M.; Chalkias, C.; Chan, L. L.; Chancharunee, S.; Chapman, C.; Charoenkwan, P.; Chasapopoulou, E.; Cheze, S.; Chuansumrit, A.; Cianciulli, P.; Dauriac, C.; Delforge, M.; Dölken, G.; Dombret, H.; Duyster, J.; Economopoulos, T.; Ehninger, G.; Elalfy, M.; El-Beshlawy, A.; Enggaard, L.; Fillet, G.; Filosa, A.; Forni, G.; Galanello, R.; Gastl, G.; Giraudier, S.; Goldfarb, A.; Grigg, A.; Gumruk, F.; Ha, S. Y.; Haase, D.; Heinrich, B.; Hertzberg, M.; Ho, J.; Hsu, H. C.; Huang, S.; Hunault-Berger, M.; Inusa, B.; Jaulmes, D.; Jensen, J.; Kattamis, A.; Kilinc, Y.; Kim, K. H.; Kinsey, S.; Kjeldsen, L.; Koren, A.; Lai, M. E.; Lai, Y.; Lee, J. W.; Lee, K. H.; Lee, S. H.; Legros, L.; Li, C.; Li, C. K.; Li, Q.; Lin, K. H.; Linkesch, W.; Lübbert, M.; Lutz, D.; Mohamed Thalha, A. J.; Mufti, G.; Muus, P.; Nobile, F.; Papadopoulos, N.; Perrotta, S.; Petrini, M.; Pfeilstöcker, M.; Piga, A.; Poole, J.; Porter, J. B.; Pungolino, E.; Quarta, G.; Ravoet, C.; Jolimont Lobbes, H. H.; Remacha, A. F.; Roy, L.; Saglio, G.; Sanz, G.; Schmugge, M.; Schots, H.; Secchi, G.; Seymour, J. F.; Shah, F.; Shah, H.; Shen, Z.; Slama, B.; Sutcharitchan, P.; Taher, A.; Tamary, H.; Tesch, H. J.; Thein, S. L.; Troncy, J.; Villegas, A.; Viprakasit, V.; Wainwright, L.; Wassmann, B.; Wettervald, M.; Will, A.; Wörmann, B.; Wright, J.; Yeh, S. P.; Yoon, S. S.; Zoumbos, N. C.; Zweegman, S.

In: Leukemia Research, Vol. 34, No. 9, 09.2010, p. 1143-1150.

Research output: Contribution to journalArticle

Gattermann, N, Finelli, C, Della Porta, M, Fenaux, P, Ganser, A, Guerci-Bresler, A, Schmid, M, Taylor, K, Vassilieff, D, Habr, D, Domokos, G, Roubert, B, Rose, C, Agaoglu, L, Alimena, G, Alonso, D, Ame, S, Angelucci, E, Arrizabalaga, B, Athanasiou-Metaxa, M, Augustson, B, Aydinok, Y, Baba, A, Baccarani, M, Beck, J, Beris, P, Beyne-Rauzy, O, Birgens, H, Bordessoule, D, Borgna-Pignatti, C, Bosly, A, Bouabdallah, K, Bowden, D, Bowen, D, Bron, D, Cappellini, MD, Capra, M, Cartron, G, Cazzola, M, Chalkias, C, Chan, LL, Chancharunee, S, Chapman, C, Charoenkwan, P, Chasapopoulou, E, Cheze, S, Chuansumrit, A, Cianciulli, P, Dauriac, C, Delforge, M, Dölken, G, Dombret, H, Duyster, J, Economopoulos, T, Ehninger, G, Elalfy, M, El-Beshlawy, A, Enggaard, L, Fillet, G, Filosa, A, Forni, G, Galanello, R, Gastl, G, Giraudier, S, Goldfarb, A, Grigg, A, Gumruk, F, Ha, SY, Haase, D, Heinrich, B, Hertzberg, M, Ho, J, Hsu, HC, Huang, S, Hunault-Berger, M, Inusa, B, Jaulmes, D, Jensen, J, Kattamis, A, Kilinc, Y, Kim, KH, Kinsey, S, Kjeldsen, L, Koren, A, Lai, ME, Lai, Y, Lee, JW, Lee, KH, Lee, SH, Legros, L, Li, C, Li, CK, Li, Q, Lin, KH, Linkesch, W, Lübbert, M, Lutz, D, Mohamed Thalha, AJ, Mufti, G, Muus, P, Nobile, F, Papadopoulos, N, Perrotta, S, Petrini, M, Pfeilstöcker, M, Piga, A, Poole, J, Porter, JB, Pungolino, E, Quarta, G, Ravoet, C, Jolimont Lobbes, HH, Remacha, AF, Roy, L, Saglio, G, Sanz, G, Schmugge, M, Schots, H, Secchi, G, Seymour, JF, Shah, F, Shah, H, Shen, Z, Slama, B, Sutcharitchan, P, Taher, A, Tamary, H, Tesch, HJ, Thein, SL, Troncy, J, Villegas, A, Viprakasit, V, Wainwright, L, Wassmann, B, Wettervald, M, Will, A, Wörmann, B, Wright, J, Yeh, SP, Yoon, SS, Zoumbos, NC & Zweegman, S 2010, 'Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study', Leukemia Research, vol. 34, no. 9, pp. 1143-1150. https://doi.org/10.1016/j.leukres.2010.03.009
Gattermann, Norbert ; Finelli, Carlo ; Della Porta, Matteo ; Fenaux, Pierre ; Ganser, Arnold ; Guerci-Bresler, Agnes ; Schmid, Mathias ; Taylor, Kerry ; Vassilieff, Dominique ; Habr, Dany ; Domokos, Gabor ; Roubert, Bernard ; Rose, Christian ; Agaoglu, L. ; Alimena, G. ; Alonso, D. ; Ame, S. ; Angelucci, E. ; Arrizabalaga, B. ; Athanasiou-Metaxa, M. ; Augustson, B. ; Aydinok, Y. ; Baba, A. ; Baccarani, M. ; Beck, J. ; Beris, P. ; Beyne-Rauzy, O. ; Birgens, H. ; Bordessoule, D. ; Borgna-Pignatti, C. ; Bosly, A. ; Bouabdallah, K. ; Bowden, D. ; Bowen, D. ; Bron, D. ; Cappellini, M. D. ; Capra, M. ; Cartron, G. ; Cazzola, M. ; Chalkias, C. ; Chan, L. L. ; Chancharunee, S. ; Chapman, C. ; Charoenkwan, P. ; Chasapopoulou, E. ; Cheze, S. ; Chuansumrit, A. ; Cianciulli, P. ; Dauriac, C. ; Delforge, M. ; Dölken, G. ; Dombret, H. ; Duyster, J. ; Economopoulos, T. ; Ehninger, G. ; Elalfy, M. ; El-Beshlawy, A. ; Enggaard, L. ; Fillet, G. ; Filosa, A. ; Forni, G. ; Galanello, R. ; Gastl, G. ; Giraudier, S. ; Goldfarb, A. ; Grigg, A. ; Gumruk, F. ; Ha, S. Y. ; Haase, D. ; Heinrich, B. ; Hertzberg, M. ; Ho, J. ; Hsu, H. C. ; Huang, S. ; Hunault-Berger, M. ; Inusa, B. ; Jaulmes, D. ; Jensen, J. ; Kattamis, A. ; Kilinc, Y. ; Kim, K. H. ; Kinsey, S. ; Kjeldsen, L. ; Koren, A. ; Lai, M. E. ; Lai, Y. ; Lee, J. W. ; Lee, K. H. ; Lee, S. H. ; Legros, L. ; Li, C. ; Li, C. K. ; Li, Q. ; Lin, K. H. ; Linkesch, W. ; Lübbert, M. ; Lutz, D. ; Mohamed Thalha, A. J. ; Mufti, G. ; Muus, P. ; Nobile, F. ; Papadopoulos, N. ; Perrotta, S. ; Petrini, M. ; Pfeilstöcker, M. ; Piga, A. ; Poole, J. ; Porter, J. B. ; Pungolino, E. ; Quarta, G. ; Ravoet, C. ; Jolimont Lobbes, H. H. ; Remacha, A. F. ; Roy, L. ; Saglio, G. ; Sanz, G. ; Schmugge, M. ; Schots, H. ; Secchi, G. ; Seymour, J. F. ; Shah, F. ; Shah, H. ; Shen, Z. ; Slama, B. ; Sutcharitchan, P. ; Taher, A. ; Tamary, H. ; Tesch, H. J. ; Thein, S. L. ; Troncy, J. ; Villegas, A. ; Viprakasit, V. ; Wainwright, L. ; Wassmann, B. ; Wettervald, M. ; Will, A. ; Wörmann, B. ; Wright, J. ; Yeh, S. P. ; Yoon, S. S. ; Zoumbos, N. C. ; Zweegman, S. / Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes : Results from the large 1-year EPIC study. In: Leukemia Research. 2010 ; Vol. 34, No. 9. pp. 1143-1150.
@article{5795a72382f14413a8216f2b879dd502,
title = "Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study",
abstract = "The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50{\%} were chelation-na{\"i}ve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-na{\"i}ve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7{\%}) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p",
keywords = "Deferasirox, Iron chelation therapy, Labile plasma iron, Myelodysplastic syndromes, Serum ferritin",
author = "Norbert Gattermann and Carlo Finelli and {Della Porta}, Matteo and Pierre Fenaux and Arnold Ganser and Agnes Guerci-Bresler and Mathias Schmid and Kerry Taylor and Dominique Vassilieff and Dany Habr and Gabor Domokos and Bernard Roubert and Christian Rose and L. Agaoglu and G. Alimena and D. Alonso and S. Ame and E. Angelucci and B. Arrizabalaga and M. Athanasiou-Metaxa and B. Augustson and Y. Aydinok and A. Baba and M. Baccarani and J. Beck and P. Beris and O. Beyne-Rauzy and H. Birgens and D. Bordessoule and C. Borgna-Pignatti and A. Bosly and K. Bouabdallah and D. Bowden and D. Bowen and D. Bron and Cappellini, {M. D.} and M. Capra and G. Cartron and M. Cazzola and C. Chalkias and Chan, {L. L.} and S. Chancharunee and C. Chapman and P. Charoenkwan and E. Chasapopoulou and S. Cheze and A. Chuansumrit and P. Cianciulli and C. Dauriac and M. Delforge and G. D{\"o}lken and H. Dombret and J. Duyster and T. Economopoulos and G. Ehninger and M. Elalfy and A. El-Beshlawy and L. Enggaard and G. Fillet and A. Filosa and G. Forni and R. Galanello and G. Gastl and S. Giraudier and A. Goldfarb and A. Grigg and F. Gumruk and Ha, {S. Y.} and D. Haase and B. Heinrich and M. Hertzberg and J. Ho and Hsu, {H. C.} and S. Huang and M. Hunault-Berger and B. Inusa and D. Jaulmes and J. Jensen and A. Kattamis and Y. Kilinc and Kim, {K. H.} and S. Kinsey and L. Kjeldsen and A. Koren and Lai, {M. E.} and Y. Lai and Lee, {J. W.} and Lee, {K. H.} and Lee, {S. H.} and L. Legros and C. Li and Li, {C. K.} and Q. Li and Lin, {K. H.} and W. Linkesch and M. L{\"u}bbert and D. Lutz and {Mohamed Thalha}, {A. J.} and G. Mufti and P. Muus and F. Nobile and N. Papadopoulos and S. Perrotta and M. Petrini and M. Pfeilst{\"o}cker and A. Piga and J. Poole and Porter, {J. B.} and E. Pungolino and G. Quarta and C. Ravoet and {Jolimont Lobbes}, {H. H.} and Remacha, {A. F.} and L. Roy and G. Saglio and G. Sanz and M. Schmugge and H. Schots and G. Secchi and Seymour, {J. F.} and F. Shah and H. Shah and Z. Shen and B. Slama and P. Sutcharitchan and A. Taher and H. Tamary and Tesch, {H. J.} and Thein, {S. L.} and J. Troncy and A. Villegas and V. Viprakasit and L. Wainwright and B. Wassmann and M. Wettervald and A. Will and B. W{\"o}rmann and J. Wright and Yeh, {S. P.} and Yoon, {S. S.} and Zoumbos, {N. C.} and S. Zweegman",
year = "2010",
month = "9",
doi = "10.1016/j.leukres.2010.03.009",
language = "English",
volume = "34",
pages = "1143--1150",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes

T2 - Results from the large 1-year EPIC study

AU - Gattermann, Norbert

AU - Finelli, Carlo

AU - Della Porta, Matteo

AU - Fenaux, Pierre

AU - Ganser, Arnold

AU - Guerci-Bresler, Agnes

AU - Schmid, Mathias

AU - Taylor, Kerry

AU - Vassilieff, Dominique

AU - Habr, Dany

AU - Domokos, Gabor

AU - Roubert, Bernard

AU - Rose, Christian

AU - Agaoglu, L.

AU - Alimena, G.

AU - Alonso, D.

AU - Ame, S.

AU - Angelucci, E.

AU - Arrizabalaga, B.

AU - Athanasiou-Metaxa, M.

AU - Augustson, B.

AU - Aydinok, Y.

AU - Baba, A.

AU - Baccarani, M.

AU - Beck, J.

AU - Beris, P.

AU - Beyne-Rauzy, O.

AU - Birgens, H.

AU - Bordessoule, D.

AU - Borgna-Pignatti, C.

AU - Bosly, A.

AU - Bouabdallah, K.

AU - Bowden, D.

AU - Bowen, D.

AU - Bron, D.

AU - Cappellini, M. D.

AU - Capra, M.

AU - Cartron, G.

AU - Cazzola, M.

AU - Chalkias, C.

AU - Chan, L. L.

AU - Chancharunee, S.

AU - Chapman, C.

AU - Charoenkwan, P.

AU - Chasapopoulou, E.

AU - Cheze, S.

AU - Chuansumrit, A.

AU - Cianciulli, P.

AU - Dauriac, C.

AU - Delforge, M.

AU - Dölken, G.

AU - Dombret, H.

AU - Duyster, J.

AU - Economopoulos, T.

AU - Ehninger, G.

AU - Elalfy, M.

AU - El-Beshlawy, A.

AU - Enggaard, L.

AU - Fillet, G.

AU - Filosa, A.

AU - Forni, G.

AU - Galanello, R.

AU - Gastl, G.

AU - Giraudier, S.

AU - Goldfarb, A.

AU - Grigg, A.

AU - Gumruk, F.

AU - Ha, S. Y.

AU - Haase, D.

AU - Heinrich, B.

AU - Hertzberg, M.

AU - Ho, J.

AU - Hsu, H. C.

AU - Huang, S.

AU - Hunault-Berger, M.

AU - Inusa, B.

AU - Jaulmes, D.

AU - Jensen, J.

AU - Kattamis, A.

AU - Kilinc, Y.

AU - Kim, K. H.

AU - Kinsey, S.

AU - Kjeldsen, L.

AU - Koren, A.

AU - Lai, M. E.

AU - Lai, Y.

AU - Lee, J. W.

AU - Lee, K. H.

AU - Lee, S. H.

AU - Legros, L.

AU - Li, C.

AU - Li, C. K.

AU - Li, Q.

AU - Lin, K. H.

AU - Linkesch, W.

AU - Lübbert, M.

AU - Lutz, D.

AU - Mohamed Thalha, A. J.

AU - Mufti, G.

AU - Muus, P.

AU - Nobile, F.

AU - Papadopoulos, N.

AU - Perrotta, S.

AU - Petrini, M.

AU - Pfeilstöcker, M.

AU - Piga, A.

AU - Poole, J.

AU - Porter, J. B.

AU - Pungolino, E.

AU - Quarta, G.

AU - Ravoet, C.

AU - Jolimont Lobbes, H. H.

AU - Remacha, A. F.

AU - Roy, L.

AU - Saglio, G.

AU - Sanz, G.

AU - Schmugge, M.

AU - Schots, H.

AU - Secchi, G.

AU - Seymour, J. F.

AU - Shah, F.

AU - Shah, H.

AU - Shen, Z.

AU - Slama, B.

AU - Sutcharitchan, P.

AU - Taher, A.

AU - Tamary, H.

AU - Tesch, H. J.

AU - Thein, S. L.

AU - Troncy, J.

AU - Villegas, A.

AU - Viprakasit, V.

AU - Wainwright, L.

AU - Wassmann, B.

AU - Wettervald, M.

AU - Will, A.

AU - Wörmann, B.

AU - Wright, J.

AU - Yeh, S. P.

AU - Yoon, S. S.

AU - Zoumbos, N. C.

AU - Zweegman, S.

PY - 2010/9

Y1 - 2010/9

N2 - The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

AB - The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

KW - Deferasirox

KW - Iron chelation therapy

KW - Labile plasma iron

KW - Myelodysplastic syndromes

KW - Serum ferritin

UR - http://www.scopus.com/inward/record.url?scp=77955268192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955268192&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2010.03.009

DO - 10.1016/j.leukres.2010.03.009

M3 - Article

C2 - 20451251

AN - SCOPUS:77955268192

VL - 34

SP - 1143

EP - 1150

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -